343 related articles for article (PubMed ID: 12873977)
1. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
[TBL] [Abstract][Full Text] [Related]
2. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
Takata M; Murata H; Saida T
Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
[TBL] [Abstract][Full Text] [Related]
4. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
5. T1799A BRAF mutations in conjunctival melanocytic lesions.
Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
[TBL] [Abstract][Full Text] [Related]
7. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
8. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
9. BRAF as a melanoma susceptibility candidate gene?
Laud K; Kannengiesser C; Avril MF; Chompret A; Stoppa-Lyonnet D; Desjardins L; Eychene A; Demenais F; Lenoir GM; Bressac-de Paillerets B;
Cancer Res; 2003 Jun; 63(12):3061-5. PubMed ID: 12810628
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
11. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
12. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
[TBL] [Abstract][Full Text] [Related]
13. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
14. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
[TBL] [Abstract][Full Text] [Related]
15. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden A; Osman I; Gai W; He D; Huang W; Davidson A; Houghton AN; Busam K; Polsky D
Cancer Res; 2003 Jul; 63(14):3955-7. PubMed ID: 12873990
[TBL] [Abstract][Full Text] [Related]
16. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
18. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
19. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
20. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
